C:\STNEXP4\QUERIES\09687800 (amended).str





chain nodes :
11 12 13 21 22 23 24
ring nodes :
1 2 3 4 5 6 7 8 9 10 14 15 16 17 18 19
chain bonds :
2-12 3-19 4-11 12-13 13-21 21-22 21-23
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 14-15 14-19 15-16 16-17 17-18
18-19
exact/norm bonds :
1-2 1-6 2-3 3-4 3-19 4-5 4-11 12-13 13-21 21-22 21-23
exact bonds :
2-12
normalized bonds :
5-6 5-7 6-10 7-8 8-9 9-10 14-15 14-19 15-16 16-17 17-18 18-19
isolated ring systems :
containing 1 : 14 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:CLASS
12:CLASS 13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 21:CLASS
22:CLASS 23:CLASS 24:CLASS 25:CLASS

```
=>
Uploading 09687800 (amended).str

L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1                STR
```




```
Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss sam
SAMPLE SEARCH INITIATED 12:56:47 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    541 TO ITERATE

100.0% PROCESSED     541 ITERATIONS                          1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         9425 TO    12215
PROJECTED ANSWERS:               1 TO       80

L2            1 SEA SSS SAM L1

=>
```

```
Uploading 09687800 (amended).str

L3      STRUCTURE UPLOADED

=> d l3
L3 HAS NO ANSWERS
L3              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l3 sss sam
SAMPLE SEARCH INITIATED 12:58:06 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    540 TO ITERATE

100.0% PROCESSED     540 ITERATIONS                                 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         9406 TO    12194
PROJECTED ANSWERS:               1 TO       80

L4            1 SEA SSS SAM L3

=> s l3 sss ful
FULL SEARCH INITIATED 12:58:14 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  10835 TO ITERATE

100.0% PROCESSED   10835 ITERATIONS                               12 ANSWERS
SEARCH TIME: 00.00.04

L5           12 SEA SSS FUL L3

=> s l5
L6           4 L5

=> d l6 1-4 bib,ab,hitstr
```

L6 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2002 ACS
AN 2001:208250 CAPLUS
DN 134:252352
TI Preparation of 3-aryl-2-arylureidoalkylquinazolin-4-ones and related compounds as mediators of hedgehog signaling pathways.
IN Baxter, Anthony David; Boyd, Edward Andrew; Guichert, Oivin M.; Price, Stephen; Rubin, Lee D.
PA Curis, Inc., USA
SO PCT Int. Appl., 177 pp.
CODEN: PIXXD2
DT Patent
LA English

Applicant's

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001019800	A2	20010322	WO 2000-US25461	20000915
WO 2001019800	A3	20011206		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1216234	A2	20020626	EP 2000-963551	20000915

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL

PRAI US 1999-154526P	P	19990916	Provisional Priority Applns
US 1999-159412P	P	19991014	
US 1999-162899P	P	19991101	
WO 2000-US25461	W	20000915	

OS MARPAT 134:252352

AB R1LX1Y1Z1LX2Y2Z2LR2 [R1, R2 = H, alkyl, (substituted) aryl, aralkyl, heteroaryl, heteroarylalkyl; L = null, alkyl, alkenyl, alkynyl, (CH2)nO(CH2)p, etc.; n, p = 0-10; X1, X2 = NR8, O, S, Se, N:N, ON:CH, heterocyclyl, bond, etc.; Y1, Y2 = CO, CS, SO2, SO, C(:NCN), heteroaryl, bond, etc.; Z1, Z2 = NR8, O, S, Se, N:N, ON:CH, heterocyclyl, bond, etc.; R8 = H, alkyl, (substituted) aryl, aralkyl, heteroaryl, heteroaralkyl, etc.], were prepd. Thus, triphosgene in EtOAc was added to 4-nitro-3-trifluoromethylaniline in EtOAc followed by stirring and reflux. The mixt. was concd., dissolved in CHCl3, and treated with 3-(4-fluorophenyl)-2-(1-methylaminoethyl)-4-oxo-3,4-dihydroquinazoline in CHCl3 to give 97% 1-[1-[3-(4-fluorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl]ethyl]-3-(3-trifluoromethyl-4-nitrophenyl)-1-methylurea. The latter inhibited sonic hedgehog-induced Gli transcription activity with IC50 <5 .mu.M.

IT **330796-20-8P 330796-21-9P 330796-24-2P**
330796-25-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 3-aryl-2-arylureidoalkylquinazolin-4-ones and related compds. as mediators of hedgehog signaling pathways)

RN 330796-20-8 CAPLUS
CN Urea, N-[2-[3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]ethyl]-N'-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



Elected Species.

RN 330796-21-9 CAPLUS
CN Urea, N-[[3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]-N'-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 330796-24-2 CAPLUS
CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)



RN 330796-25-3 CAPLUS
CN Urea, N-(2,6-dichloro-4-pyridinyl)-N'-[[3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2002 ACS
AN 1998:352629 CAPLUS
DN 129:27954
TI Quinazolinone derivatives as cholecystokinin (CCK) ligands
IN Padia, Janak Khimchand
PA Warner-Lambert Co., USA
SO U.S., 23 pp., Cont.-in-part of U.S. Ser. No. 287,454.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5756502	A	19980526	US 1995-500436	19950710
	US 5869665	A	19990209	US 1997-826843	19970408
PRAI	US 1994-287454		19940808		
	US 1995-500436		19950710		

OS CASREACT 129:27954; MARPAT 129:27954
AB The title compds. [I; W, X, Y, Z = CR3, CR4, CR5, CR6, N, etc.; M = O, S; B = bond or (un)substituted alkylene; A = R1NCO(CH2)n, CONR11(CH2)n, etc.; n = 0, 1; R1, R2 = C1-6 alkyl, (un)substituted aryl, etc.; R3-R6 = H, OH, alkoxy, etc.; R11 = H, lower alkyl] are prepd. I with good binding affinity for the CCK-A and CCK-B receptors are useful agents to suppress appetite, reduce gastric acid secretion, and the like. Thus, 2-(aminomethyl)-3-[3-(methylethoxy)phenyl]-4(3H)-quinazoline (prepn. given) was reacted with 3-methylphenyl isocyanate to give 50% the title compd. (II), which showed CCK-A and CCK-B receptor binding affinities (Ki) of 1637 and 879 nm resp.
IT **189937-54-0P 189937-57-3P 189937-58-4P**
189937-60-8P 189937-63-1P 189937-64-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(quinazolinone derivs. as cholecystokinin (CCK) ligands)
RN 189937-54-0 CAPLUS
CN Urea, N-[[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]methyl]-N'-(3-methylphenyl)- (9CI) (CA INDEX NAME)



RN 189937-57-3 CAPLUS
CN Urea, N-(4-bromophenyl)-N'-[[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)



RN 189937-58-4 CAPLUS
CN Urea, N-[[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]methyl]-N'-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 189937-60-8 CAPLUS
CN Benzoic acid, 3-[[[[[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]methyl]amino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 189937-63-1 CAPLUS
CN Benzenesulfonamide, N-[[[[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]methyl]amino]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 189937-64-2 CAPLUS
CN Urea, N-(4-bromophenyl)-N'-[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 83 THERE ARE 83 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2002 ACS
AN 1998:169718 CAPLUS
DN 128:238969
TI Novel Nonpeptide CCK-B Antagonists: Design and Development of Quinazolinone Derivatives as Potent, Selective, and Orally Active CCK-B Antagonists
AU Padia, Janak K.; Field, Mark; Hinton, Joanna; Meecham, Ken; Pablo, Julius; Pinnock, Rob; Roth, Bruce D.; Singh, Lakhbir; Suman-Chauhan, Nirmala; Trivedi, Bharat K.; Webdale, Louise
CS Departments of Chemistry and of Pharmacokinetics and Drug Metabolism, Parke-Davis Pharmaceutical Research Division of Warner-Lambert Company, Ann Arbor, MI, 48105, USA
SO Journal of Medicinal Chemistry (1998), 41(7), 1042-1049
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
AB Urea-linked quinazolines [I; R = (un)substituted Ph, cyclohexyl; R1 = (un)substituted Ph, 3-pyridyl, 1-naphthyl] were prepd. as selective orally active CCK-B antagonists. Thus, thioxoquinazolinones II (prepd. from anthranilic acid and the requisite isothiocyanate) were treated with hydrazine gave the 2-hydrazino compds. which were then treated with an isocyanate to give I. Representative compds. of this series were tested in the functional assay, i.e., guinea pig stomach strip assay, and showed pure antagonist profiles. I [R = 3-(tert-butoxycarbonyl)phenyl, R1 = 3-isopropoxyphenyl] and I [R = 3-cyanophenyl, R1 = 3-(dimethylamino)phenyl] (III) were orally active in the elevated rat X-maze test and showed dose-dependent anxiolytic-like action. These compds. were also evaluated for their pharmacokinetic profile. The abs. oral bioavailability of III was 22% in rats.
IT **189937-57-3P 189937-64-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of urea-linked quinazolinones as selective CCK-B receptor antagonists)
RN 189937-57-3 CAPLUS
CN Urea, N-(4-bromophenyl)-N'-[[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)



RN 189937-64-2 CAPLUS
CN Urea, N-(4-bromophenyl)-N'-[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]ethyl]- (9CI) (CA INDEX NAME)


Br
O
N
CH2
CH2
NH
C
NH
N
O
OPr-i

L6 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2002 ACS
AN 1997:285638 CAPLUS
DN 126:343533
TI Design and synthesis of novel nonpeptide CCK-B receptor antagonists
AU Padia, J. K.; Chilvers, H.; Daum, P.; Pinnock, R.; Suman-Chauhan, N.; Webdale, L.; Trivedi, B. K.
CS Division of Warner-Lambert Company, Department of Chemistry, Parke-Davis Pharmaceutical Research, Ann Arbor, MI, 48105, USA
SO Bioorganic & Medicinal Chemistry Letters (1997), 7(7), 805-810
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier
DT Journal
LA English
AB A novel hybrid series of nonpeptide CCK-B receptor antagonists, quinazolinones I (R = 3-Me, 4-Br, 3-CO2Et, etc., L = CH2, CH2CH2, X = O, S, Y = NH, NHCH2, NHSO2), has been designed from two known series derived from asperlicin. An efficient synthesis of 2-aminoquinazolinone, an intermediate for the synthesis of a targeted analog, has been developed.
IT **189937-54-0P 189937-57-3P 189937-58-4P**
189937-59-5P 189937-60-8P 189937-62-0P
189937-63-1P 189937-64-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and CCK-B receptor antagonist activity of quinazolinones)
RN 189937-54-0 CAPLUS
CN Urea, N-[[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]methyl]-N'-(3-methylphenyl)- (9CI) (CA INDEX NAME)



RN 189937-57-3 CAPLUS
CN Urea, N-(4-bromophenyl)-N'-[[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)



RN 189937-58-4 CAPLUS
CN Urea, N-[[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-

quinazolinyl]methyl]-N'-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 189937-59-5 CAPLUS
CN Urea, N-[[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]methyl]-N'-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 189937-60-8 CAPLUS
CN Benzoic acid, 3-[[[[[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]methyl]amino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 189937-62-0 CAPLUS
CN Urea, N-[(4-bromophenyl)methyl]-N'-[[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)



RN 189937-63-1 CAPLUS
CN Benzenesulfonamide, N-[[[[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]methyl]amino]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 189937-64-2 CAPLUS
CN Urea, N-(4-bromophenyl)-N'-[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]ethyl]- (9CI) (CA INDEX NAME)



```
=> d his

     (FILE 'HOME' ENTERED AT 12:56:13 ON 20 OCT 2002)

     FILE 'REGISTRY' ENTERED AT 12:56:19 ON 20 OCT 2002
L1             STRUCTURE UPLOADED
L2           1 S L1 SSS SAM
L3             STRUCTURE UPLOADED
L4           1 S L3 SSS SAM
L5          12 S L3 SSS FUL

     FILE 'CAPLUS' ENTERED AT 12:58:34 ON 20 OCT 2002
L6           4 S L5

     FILE 'CAOLD' ENTERED AT 12:59:09 ON 20 OCT 2002

=> s l5
L7           0 L5

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.38     159.96

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -2.48

STN INTERNATIONAL LOGOFF AT 12:59:20 ON 20 OCT 2002
```